Scholar Rock Holding Co. (NASDAQ:SRRK) Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC increased its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 48.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,275 shares of the company's stock after purchasing an additional 8,601 shares during the period. ProShare Advisors LLC's holdings in Scholar Rock were worth $1,136,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. FMR LLC raised its stake in shares of Scholar Rock by 33.7% during the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock worth $589,316,000 after purchasing an additional 3,439,215 shares during the last quarter. Marshall Wace LLP increased its stake in Scholar Rock by 1,283.7% in the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock valued at $127,301,000 after buying an additional 2,732,546 shares during the period. Norges Bank purchased a new position in Scholar Rock during the 4th quarter worth $86,043,000. Fairmount Funds Management LLC acquired a new stake in shares of Scholar Rock in the 4th quarter worth $84,839,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of Scholar Rock in the fourth quarter valued at about $68,930,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Price Performance

Shares of NASDAQ SRRK traded up $0.04 during trading on Wednesday, hitting $30.51. 82,481 shares of the company were exchanged, compared to its average volume of 1,265,849. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a market cap of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37. The firm's fifty day moving average price is $30.63 and its 200 day moving average price is $36.00.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same quarter in the prior year, the firm earned ($0.59) EPS. On average, sell-side analysts expect that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 6,500 shares of the company's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total value of $215,020.00. Following the sale, the insider now owns 71,750 shares of the company's stock, valued at approximately $2,373,490. This represents a 8.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of Scholar Rock stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the transaction, the chief financial officer now directly owns 111,345 shares of the company's stock, valued at $3,966,108.90. This trade represents a 56.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,798 shares of company stock valued at $5,482,238 in the last ninety days. Corporate insiders own 13.30% of the company's stock.

Analysts Set New Price Targets

Separately, Wedbush reissued an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Scholar Rock presently has an average rating of "Buy" and an average price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.